Last reviewed · How we verify
Crizotinib Oral Capsule [Xalkori] — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Crizotinib Oral Capsule [Xalkori] (crizotinib-oral-capsule-xalkori) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Crizotinib Oral Capsule [Xalkori] TARGET | crizotinib-oral-capsule-xalkori | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Crizotinib Oral Capsule [Xalkori] CI watch — RSS
- Crizotinib Oral Capsule [Xalkori] CI watch — Atom
- Crizotinib Oral Capsule [Xalkori] CI watch — JSON
- Crizotinib Oral Capsule [Xalkori] alone — RSS
Cite this brief
Drug Landscape (2026). Crizotinib Oral Capsule [Xalkori] — Competitive Intelligence Brief. https://druglandscape.com/ci/crizotinib-oral-capsule-xalkori. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab